Molecular Imaging Reveals Rapid Reduction of Endothelial Activation in Early Atherosclerosis With Apocynin Independent of Antioxidative Properties

Abstract

OBJECTIVE Anti-oxidative drugs continue to be developed for the treatment of atherosclerosis. Apocynin is an NADPH-oxidase-inhibitor with anti-inflammatory properties. We used contrast enhanced ultrasound (CEU) molecular imaging to assess whether short-term apocynin therapy in atherosclerosis reduces vascular oxidative stress and endothelial activation APPROACH AND RESULTS Genetically-modified mice with early atherosclerosis were studied at baseline and after 7 days of therapy with apocynin (4mg/kg/d I.P.) or saline. CEU molecular imaging of the aorta was performed with microbubbles targeted to vascular cell adhesion molecule 1 (VCAM-1; MBV), to platelet GPIbα (MBPl), and control microbubbles (MBCtr). Aortic VCAM-1 was measured using Western Blot. Aortic ROS generation was measured using a lucigenin assay. Hydroethidine (HE) oxidation was used to assess aortic superoxide generation. Baseline signal for MBV (1.3±0.3 A.U.) and MBPl (1.5±0.5 A.U.) was higher than for MBCtr (0.5±0.2 A.U., p<0.01). In saline-treated animals, signal did not significantly change for any microbubble agent whereas short-term apocynin significantly (p<0.05) reduced VCAM-1 and platelet signal (MBV: 0.3±0.1, MBPl: 0.4±0.1 MBCtr: 0.3±0.2 A.U., p=0.6 between agents). Apocynin reduced aortic VCAM-1 expression by 50% (p<0.05). However, apocynin therapy did not reduce either ROS content, superoxide generation, or macrophage content. CONCLUSIONS Short-term treatment with apocynin in atherosclerosis reduces endothelial cell adhesion molecule expression. This change in endothelial phenotype can be detected by molecular imaging before any measurable decrease in macrophage content, and is not associated with a detectable change in oxidative burden.

Noninvasive Molecular Ultrasound Monitoring of Vessel Healing After Intravascular Surgical Procedures in a Preclinical Setup

“…23 It has already been used for visualizing aortic atherosclerotic lesions by molecular ultrasound. [24][25][26] Despite its major application in atherosclerosis, VCAM-1 is also an acute inflammatory marker that is highly expressed after vascular injury, and it plays a major role in the formation of neointima and restenosis. 27 It was previously described that VCAM-1 is expressed by both ECs 28 and VSMCs 29,30 in atherosclerotic arteries.…”

Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association

“…Experimental atherosclerosis has been quantified and characterized by several modalities, including ultrasound, 202 magnetic resonance imaging, 203,204 and positron emission tomography, sometimes in combination with computed tomography. 205,206 There have also been applications to experimental atherosclerosis using multimodality imaging such as positron emission tomography/magnetic resonance imaging.…”

Pathology of human plaque vulnerability: Mechanisms and consequences of intraplaque haemorrhages

“…However, the frequent presence of calcifications, also detected by this technique, represents a limitation. This method [101] could be completed by a specific molecular imaging approach, targeting different molecules including vascular cell adhesion molecule [102], platelet glycoproteins and p-selectin. These approaches are now also being experimentally tested for their theragnostic potentials.…”